Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME 1111

Next Previous
Drug Profile

ME 1111

Alternative Names: ME-1111

Latest Information Update: 27 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meiji Seika Pharma
  • Class Antifungals; Cresols; Pyrazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Succinate cytochrome c oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Onychomycosis

Most Recent Events

  • 14 Feb 2020 Meiji Seika Pharma completes a phase II trial in Onychomycosis in Japan (Topical) (JapicCTI183840)
  • 01 Feb 2018 Phase-II clinical trials in Onychomycosis in Japan (Topical) (JapicCTI183840)
  • 01 Feb 2018 Meiji Seika Pharma plans a phase II trial for Onychomycosis in Japan (JapicCTI183840)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top